Literature DB >> 35039931

Necrotic reshaping of the glioma microenvironment drives disease progression.

Steven M Markwell1, James L Ross2, Cheryl L Olson1, Daniel J Brat3.   

Abstract

Glioblastoma is the most common primary brain tumor and has a dismal prognosis. The development of central necrosis represents a tipping point in the evolution of these tumors that foreshadows aggressive expansion, swiftly leading to mortality. The onset of necrosis, severe hypoxia and associated radial glioma expansion correlates with dramatic tumor microenvironment (TME) alterations that accelerate tumor growth. In the past, most have concluded that hypoxia and necrosis must arise due to "cancer outgrowing its blood supply" when rapid tumor growth outpaces metabolic supply, leading to diffusion-limited hypoxia. However, growing evidence suggests that microscopic intravascular thrombosis driven by the neoplastic overexpression of pro-coagulants attenuates glioma blood supply (perfusion-limited hypoxia), leading to TME restructuring that includes breakdown of the blood-brain barrier, immunosuppressive immune cell accumulation, microvascular hyperproliferation, glioma stem cell enrichment and tumor cell migration outward. Cumulatively, these adaptations result in rapid tumor expansion, resistance to therapeutic interventions and clinical progression. To inform future translational investigations, the complex interplay among environmental cues and myriad cell types that contribute to this aggressive phenotype requires better understanding. This review focuses on contributions from intratumoral thrombosis, the effects of hypoxia and necrosis, the adaptive and innate immune responses, and the current state of targeted therapeutic interventions.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Glioblastoma; Necrosis; Tumor-associated macrophages

Mesh:

Year:  2022        PMID: 35039931     DOI: 10.1007/s00401-021-02401-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   15.887


  250 in total

1.  CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin.

Authors:  S Basu; R J Binder; T Ramalingam; P K Srivastava
Journal:  Immunity       Date:  2001-03       Impact factor: 31.745

2.  Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway.

Authors:  S Basu; R J Binder; R Suto; K M Anderson; P K Srivastava
Journal:  Int Immunol       Date:  2000-11       Impact factor: 4.823

3.  EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma.

Authors:  Zhenyi An; Christiane B Knobbe-Thomsen; Xiaohua Wan; Qi Wen Fan; Guido Reifenberger; William A Weiss
Journal:  Cancer Res       Date:  2018-11-06       Impact factor: 12.701

4.  Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres.

Authors:  Eli E Bar; Alex Lin; Vasiliki Mahairaki; William Matsui; Charles G Eberhart
Journal:  Am J Pathol       Date:  2010-07-29       Impact factor: 4.307

5.  Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors.

Authors:  Andrea Babelova; Kristin Moreth; Wasiliki Tsalastra-Greul; Jinyang Zeng-Brouwers; Oliver Eickelberg; Marian F Young; Peter Bruckner; Josef Pfeilschifter; Roland M Schaefer; Hermann-Josef Gröne; Liliana Schaefer
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

6.  HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration.

Authors:  Rosaria Bassi; Paola Giussani; Viviana Anelli; Thomas Colleoni; Marco Pedrazzi; Mauro Patrone; Paola Viani; Bianca Sparatore; Edon Melloni; Laura Riboni
Journal:  J Neurooncol       Date:  2007-11-02       Impact factor: 4.130

7.  PDGF family function and prognostic value in tumor biology.

Authors:  Michael Bartoschek; Kristian Pietras
Journal:  Biochem Biophys Res Commun       Date:  2018-06-23       Impact factor: 3.575

8.  Canonical NFκB signaling in myeloid cells is required for the glioblastoma growth.

Authors:  B R Achyut; Kartik Angara; Meenu Jain; Thaiz F Borin; Mohammad H Rashid; A S M Iskander; Roxan Ara; Ravindra Kolhe; Shelby Howard; Natasha Venugopal; Paulo C Rodriguez; Jennifer W Bradford; Ali S Arbab
Journal:  Sci Rep       Date:  2017-10-23       Impact factor: 4.379

9.  RNA Sequencing Reveals Small and Variable Contributions of Infectious Agents to Transcriptomes of Postmortem Nervous Tissues From Amyotrophic Lateral Sclerosis, Alzheimer's Disease and Parkinson's Disease Subjects, and Increased Expression of Genes From Disease-Activated Microglia.

Authors:  James P Bennett; Paula M Keeney; David G Brohawn
Journal:  Front Neurosci       Date:  2019-03-28       Impact factor: 4.677

10.  Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for the treatment of glioma.

Authors:  John A Barrett; Hongliang Cai; John Miao; Pranay D Khare; Paul Gonzalez; Jessica Dalsing-Hernandez; Geeta Sharma; Tim Chan; Laurence J N Cooper; Francois Lebel
Journal:  Cancer Gene Ther       Date:  2018-05-14       Impact factor: 5.987

View more
  2 in total

Review 1.  Neutrophils: New Critical Regulators of Glioma.

Authors:  Guanyu Wang; Jinpeng Wang; Chaoshi Niu; Yan Zhao; Pengfei Wu
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

Review 2.  Tumor Temperature: Friend or Foe of Virus-Based Cancer Immunotherapy.

Authors:  Jason P Knapp; Julia E Kakish; Byram W Bridle; David J Speicher
Journal:  Biomedicines       Date:  2022-08-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.